- Home
- GILD vs ADI Comparison
GILD vs ADI Comparison
Compare GILD & ADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | ADI |
|---|---|---|
| Founded | 1987 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0B | 179.0B |
| IPO Year | 2003 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | ADI |
|---|---|---|
| Price | $138.92 | $390.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 22 |
| Target Price | $148.39 | ★ $385.45 |
| AVG Volume (30 Days) | ★ 6.4M | 3.6M |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.55% | 1.13% |
| EPS Growth | ★ 1684.21 | 39.02 |
| EPS | N/A | ★ 4.09 |
| Revenue | ★ $24,689,000,000.00 | $6,200,942,000.00 |
| Revenue This Year | $4.68 | $28.41 |
| Revenue Next Year | $6.04 | $10.25 |
| P/E Ratio | ★ N/A | $95.21 |
| Revenue Growth | 9.98 | ★ 21.41 |
| 52 Week Low | $108.46 | $223.47 |
| 52 Week High | $157.29 | $449.52 |
Technical Indicators
Market Signals| Indicator | GILD | ADI |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 56.33 |
| Support Level | $128.15 | $382.27 |
| Resistance Level | $142.97 | $404.53 |
| Average True Range (ATR) | 3.73 | 10.66 |
| MACD | 0.66 | 2.96 |
| Stochastic Oscillator | 95.09 | 91.82 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.